Breaking News

Gallus Enters ADC Mfg. Agreement with Progenics

To produce prostate cancer drug at its commercial facility in St. Louis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gallus BioPharmaceuticals, LLC has been selected by Progenics Pharmaceuticals, Inc. to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in its PSMA ADC product candidate. Gallus will produce the antibody at its commercial manufacturing facility in St. Louis, MO.   PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug to prostate cancer cells by targeting PSMA, a protein that is a biomarker of prostate cancer....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters